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Pharmacophore modelMembrane active antimicrobials are a promising newgeneration of antibiotics that hold the potential to avert an-
tibiotic resistance. However, poor understanding of the action mechanism and the lack of general design princi-
ples have impeded their development. Herewe extend the concept of fragment based drug design and propose a
pharmacophore model based on ﬁrst principles for the design of membrane active antimicrobials against Gram
positive pathogens. Elaborating on a natural xanthone-based hydrophobic scaffold, two derivatives of the
pharmacophoremodel are proposed, and these demonstrate excellent antimicrobial activity. Rigorousmolecular
dynamics simulations combined with biophysical experiments suggest a three-step mechanism of action
(absorption–translocation–disruption) which allows us to identify key factors for the practical optimization of
each fragment of the pharmacophore. Moreover, the model matches the structures of several membrane active
antimicrobials which are currently in clinical trials. Our model provides a novel and rational approach for the
design of bactericidal molecules that target the bacterial membrane.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Widespread antibiotic resistance has become a global healthcare
problem [1,2]. Resistant pathogens have been readily found against
every class of antibiotics, including vancomycin and the recently ap-
proved drugs such as linezolid and daptomycin. As a result, treatment
of infections caused by resistant pathogens such as vancomycin-
resistant enterococcus (VRE) and methicillin-resistant Staphylococcus
aureus (MRSA) pose substantial challenges [3–5]. Membrane active
antimicrobials [6] such as antimicrobial peptides (AMPs) [7,8] and syn-
thetic peptidomimetics [9,10] may offer a potential solution to this
problem, as these molecules act on the bacterial membrane, which is
evolutionarily conserved and difﬁcult for the bacteria to develop resis-
tance. In contrast, commonly used antibiotics interfere with bacterial
biosynthesis, centering on proteins which are easily mutated resultinge (A*-STAR), 30 Biopolis Street,
e Research Institute, 11 Third
), rwbeuerman@gmail.comin loss of recognition of the “docking site” by the antibiotic, thus render-
ing them ineffective. Compared with AMPs, synthetic peptidomimetics
are commercially more promising due to their simple structures,
lower costs and high stability. The development of rational principles
for the design of membrane active peptidomimetics would stimulate
this developing area [11].
The action mechanism of AMPs at the molecular level has been ex-
tensively studied experimentally and computationally in the past sever-
al decades and severalmodes of action have been proposed, namely, the
barrel-stave model, the toroidal model and the carpet model [12–15].
However, few atomistic insights are available for the action mechanism
of synthetic peptidomimetics, which has impeded their further devel-
opment. In silico methods such as molecular docking [16], in principle,
could provide atomic level information of molecular interactions, but
these are largely limited to the design of traditional antibiotics. For the
design of membrane active AMPs/peptidomimetics, molecular docking
usually fails because of a poor understanding of the actual action mech-
anism, the lack of well-deﬁned molecular cavities for drug binding in
the membrane, the dynamic nature of the membranes due to their
ﬂuidity and the diverse binding modes of these molecules to the
membrane. Instead, molecular dynamics (MD) simulations are now
commonly being used to understand the detailed atomistic dynamics
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peptidomimetics [12,14,17].
A number of simulation and experimental studies have shown that
both hydrophobic and electrostatic interactions are important in the
interactions of AMPs with the bacterial membrane [12,18,19]. This is
because most AMPs are amphiphilic and can insert their hydrophobic
moieties into the lipid tail region of the bacterial membrane, while
their cationic groups interact with the anionic head groups. To mimic
the amphiphilic structure of AMPs, based on different hydrophobic
scaffolds, several synthetic peptidomimetics have been reported in the
last decade. For example, using an arylamide scaffold, Tew et al.
have designed a series of cationic antimicrobial foldamers, such as
PMX-30016 and PMX-30063 to mimic the interaction of maganin
with bacterial membranes [17]. Using porphyrin as a hydrophobic
scaffold, Ooi et al. added two cationic groups and developed a new
membrane active antimicrobial XF-73 with rapid bacterial killing
and excellent antimicrobial activity [20]. Other hydrophobic scaffolds
have also been used in the development of the membrane active
peptidomimetics such as LTX-109 [21], CSA-13 [22] and BPMTAs [23].
Using a similar approach, our group selected alpha-mangostin, a natu-
rally occurring xanthone isolated from the pericarp of the tropical fruit
mangosteen as the hydrophobic scaffold because of its high membrane
afﬁnity [24]. We modiﬁed this scaffold by adding two cationic groups
and obtained a series of amphiphilic xanthone analogues [25]. One of
the xanthone analogues AM0016 (Fig. 1) showed excellent antimicrobi-
al activity and rapid killing kinetics, demonstrating great potential for
further structural optimization.
Microbial killing by membrane active antimicrobials is a complex
process. For Gram positive pathogens such as MRSA, the disruption of
the inner membrane is usually the rate limiting step [6], while for
Gram negative pathogens, the thick outer membrane made up of lipo-
polysaccharide (LPS) molecules is a signiﬁcant barrier to most antimi-
crobial molecules and permeation through such barriers is most likely
a critical rate limiting step [26–28]. In this study, our goal is to develop
practical principles for the design of new antimicrobials against Gram
positive pathogens, particularly MRSA; therefore we focus only on the
bacterial innermembrane. From a structural point of view, the bacterial
inner membrane can be decomposed into three fragments: two anionic
head group regions and one hydrophobic region, and it is this decompo-
sition that provides the basis for the development of a fragment based
strategy [29] (Fig. 1). We hypothesize that a molecule that perturbs all
three fragments of the bacterial inner membrane will likely have high
membrane activity. As such, we propose a bola-like pharmacophore
model that consists of two cationic arms and one hydrophobic scaffold,Fig. 1. The schematic view of the xanthone based pharmacophore model containing ﬁve frag
ﬂexible linkers. The bacterial membrane contains a high percentage of anionic lipids. Initially t
the molecule overcomes an energy barrier and undergoes a conformational change, resulting
than the U-shaped conformation. AM0016 and AM0019 are the two derivatives of the pharmawhich complementarily interact with the two anionic head group frag-
ments and the lipid tail fragment, respectively. The hydrophobic scaf-
fold provides afﬁnity for the lipid tails of the bacterial membrane,
while the two cationic groups preferentially interact with the two an-
ionic head group regions of the bacterial membrane. One can deduce
from themodel that upon initial adsorption on the surface of the bacte-
rial outer leaﬂet, the molecule would adopt a U-shaped conformation,
with both cationic groups interacting with the head groups of the
outer leaﬂet and the hydrophobic scaffold embedded in the lipid tail re-
gion. To achieve a transmembrane conformation, one of the cationic
groups needs to translocate across the lipid tail region of themembrane,
which, at ﬁrst glance appears energetically prohibitive and hence
unlikely; however, we ﬁnd that this indeed is possible, albeit at high
drug concentrations, as we will demonstrate below.
In this study, we employ a multi-disciplinary approach which in-
volves MD simulations, biophysical and microbiological experiments
to decipher the detailed action mechanism of the pharmacophore
model using AM0016 as a model compound (Fig. 1). First we vary
the structure of the hydrophobic scaffold and the cationic groups of
AM0016 to examine the role of each fragment using MD simulations.
The resulting new analogues are synthesized and validated using
biophysical and microbiological experiments. Finally we discuss some
principles for the practical design of active bolaamphiphilic molecules
against bacterial membranes.
2. Results
2.1. Role of the hydrophobic scaffold
In the pharmacophore model, the role of the hydrophobic scaffold is
to drive the molecule deeply into the hydrophobic region of the mem-
brane followed by translocation. Hydrophobic scaffolds with high afﬁn-
ity for the lipid tails are likely to partition more into the membrane,
i.e., have high interfacial activity [30]. This is an energetically favourable
step and requires the identiﬁcation of a proper hydrophobic scaffold
that most optimally embeds into the membrane. Alpha-mangostin has
been demonstrated, through our development of AM0016 [24,25], to
be an appropriate scaffold. Two structural properties, notably the pla-
narity and the hydrophobicity of the scaffold favour its penetration
into the hydrophobic region of the bacterial membrane. However,
high hydrophobicity of a molecule is believed to lead to high toxicity
to human membranes [31–33]. Thus it is important to estimate the op-
timum hydrophobicity of the scaffold required to maintain the afﬁnity
for the lipid tails of the bacterial membrane. As shown in Fig. 2a, thements: alpha-mangostin as the hydrophobic core, two cationic terminal groups and two
he molecule gets adsorbed with U-shaped conformations; at high surface concentrations,
in a trans-membrane conformation, which can induce larger membrane perturbations
cophore model.
Fig. 2. (a) Chemical structures ofMAN, XAN andXAN-016; (b) transfer free energies of alpha-mangostin (MAN) and xanthone analoguewithout the isoprenyl groups (XAN) from solvent;
(c) conﬁguration of 16 XAN molecules on the bacterial membrane with 16 XAN molecules initially put on top of the bacterial membrane; (d) conﬁguration of 16 MANmolecules on the
bacterial membrane with the 16 MAN molecules initially put on top of the bacterial membrane; (e) conﬁguration of 16 XAN molecules on the bacterial membrane with the 16 XAN
molecules initially put at the centre of the bacterial membrane; (f) conﬁguration of 16 MANmolecules on the bacterial membrane with the 16 MANmolecules initially put at the centre
of the bacterial membrane.
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bicity of alpha-mangostin [24], and hence it is important to explore
whether the xanthone analogue with the isoprenyl group removed
could still maintain the afﬁnity for the lipid tail region of the bacterial
membrane. To such purpose, we ﬁrst compared the afﬁnities of alpha-
mangostin (referred to as MAN hereafter) and the analogue with
isoprenyl groups removed (referred to as XAN) for the bacterial
membrane using MD simulations.
To estimate the ability of these two molecules to partition into the
membrane, we calculated their transfer free energies from solvent
using umbrella sampling and the weighted histogram analysis method
[34] (Fig. 2b). It is clear that MAN encounters lower transfer free ener-
gies than XAN and hence can penetrate more easily into the bacterial
membrane. This suggests that the two isoprenyl groups contribute
signiﬁcantly to the afﬁnity of alpha-mangostin for the lipid tail region
of the bacterial membrane. In contrast, in the absence of the isoprenyl
groups, the hydrophobicity is attenuated by the polar groups in the ar-
omatic rings, resulting in the loss of afﬁnity of XAN for the lipid tails.
The transfer free energies of MAN and XANwere calculated using a sin-
gle molecule, which corresponds to a low compound/lipid ratio. High
compound/lipid ratios were explored by carrying out microsecond
long conventional MD simulations at a compound/lipid ratio of 16/128
for both molecules. Fig. 2c and d show that at a higher concentration,
MAN can penetrate and accumulate in the lipid tail region of the
bacterial membrane, while XAN prefers to remain on the surface of
the bacterial membrane, consistent with the free energy results. It is of
course possible that XAN may penetrate at longer simulation times. To
examine this, we ran a separate simulation with 16 MAN or 16 XAN
molecules initially placed in the lipid tail region of the bacterial mem-
brane. At the end of the simulation, most of the MAN molecules
remained in the lipid tail region of the bacterial membrane, while
none of the XAN molecules remained deeply embedded in the lipid
tail region (Fig. 2e and f). Among the 16 XAN molecules, 11 moved
out of the bacterialmembrane on to themembrane surface. The remain-
ing 5 XANmolecules moved close to the membrane surface, remainingjust beneath the head groups. The inability of XAN to partition sufﬁ-
ciently into the lipid tail region of the bacterial membrane indicates
that the two isoprenyl groups serve as membrane probes and thus are
a critical component of the xanthone scaffold.
To validate the importance of the isoprenyl group, we synthesized a
new compound XAN-016, with the isoprenyl group removed from
AM0016 (Fig. 2a). An in vitro antimicrobial test showed little or no
activity of XAN-016 against various Staphylococcus aureus strains
including MRSA, with minimum inhibitory concentrations (MIC)
above 50 μg/mL (Table 1), consistent with the observations made
from the simulation. Based on the simulation and experimental results,
we retained the isoprenyl groups on the xanthone scaffold of the
pharmacophore model and next examined the role of the cationic
groups.
2.2. Role of the terminal cationic groups
The main difference between the physicochemical characteristics of
the bacterial membrane and the mammalian membrane lies in their
head groups, with the former being anionic and the latter zwitterionic.
The cationic fragments of the pharmacophore model can selectively in-
teract with the anionic head groups via electrostatic interactions and
thus can be critical for antimicrobial activity as well as for selectivity.
We have previously found that cationic groups with high pKa values
and low hydrophobicity are essential for antimicrobial activity as well
as selectivity [25]. To further explore the selectivity, we mutated the
diethylamide group (pKa 10.95) of AM0016 to guanidinium (pKa
12.48), creating a new compound AM0019 (Figs. 1 and S1). We further
hypothesized that the lower hydrophobicity of the guanidinium group
may also result in reduced toxicity of AM0019 against mammalian
membranes.
The afﬁnities of the two analogues (AM0016 and AM0019) for a
model bacterial membrane were estimated by calculating their transfer
free energies from solvent. As illustrated in our model, the cationic
group of the drug molecule needs to overcome a free energy barrier
Table 1
Minimum inhibitory concentrations (aMIC) of xanthone analogues (μg/mL).
Description XAN-016 AM0016 AM0019
MRSA 9808R Methicillin-resistant staphylococcus aureus (+)b N50 1.56 6.25
SA DM 4001R Clinical isolates Staphylococcus aureus (+) N50 1.56 3.125
MRSA 21455 Methicillin-resistant staphylococcus aureus (+) N50 0.39 6.25
BC 11778 Bacillus cereus (+) N50 3.125 6.25
PA DM23155 Clinical isolates Pseudomonas aeruginosa (−)c N50 N25 N25
Kleb DM4299 Clinical isolates Klebsiella pneumonia (−) N50 N25 N25
a The MIC is repeated two time for each assay, and the standard deviation is +/− 1x MIC.
b (+) denotes Gram positive strain.
c (−) denotes Gram negative strain.
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conformational change from theU-shape to the transmembrane confor-
mations (Fig. 3a). This conformational change depends on the inherent
deformability of the membrane and other ‘hidden’ degrees of freedom,
and may lead to hysteresis during the computation if the centre of
mass is pulled in the forward and reverse directions. As the free energy
barrier arises mainly from the introduction of the cationic group in the
lipid tail region, we chose the distance between one of the cationic
groups and the bilayer centre as the reaction coordinate. As shown in
Fig. 3b, both AM0016 and AM0019 show qualitatively similar trends
in their translocation free energies, indicating similar modes of actions.
The two free energyminima, located at 2 nmand−1 nm, correspond to
the U-shaped and the transmembrane conformations, respectively,
while the free energy barrier corresponds to the transition state that
characterizes the crossing of the hydrophobic region of the membrane
by the cationic group (Fig. 3a). However, the free energy proﬁles of
the two molecules are quantitatively different. AM0019 shows a higher
free energy barrier than AM0016 at the transition state because the
guanindine group of AM0019 is less hydrophobic than the diethalamine
group of AM0016. Moreover, the high hydrophobicity of diethalamine
group also incurs less desolvation costs when adsorbed on the surface
of the bacterial membrane, as seen from themore favourable free ener-
gy minimum of AM0016 in its U-shaped conformation (around 2 nm).Fig. 3. (a) Snapshots showing the conformational change of AM0016 during penetration
into the bacterial membrane. (b) Transfer free energy of AM0016 and AM0019 across
the bacterial membrane as a function of the distance between one cationic group and
the bilayer centre.In summary, the above simulation results reveal two possible con-
formations of AM0016 and AM0019 occurring sequentially—ﬁrst
the U-shaped and then the transmembrane conformations.
The high free energy barrier for the conformational change is obtain-
ed using one molecule of AM0016 or AM0019 and 72 molecules of
lipids, corresponding to a low drug concentration. As the surface
concentration of AM0016/AM0019 on the outer leaﬂet increases, the
anionic charges of the outer leaﬂet will gradually be neutralized. This
will result in an asymmetry of charges experienced by the cationic
sidechains, with a strong electrostatic pull towards the inner leaﬂet
which does not experience charge neutralization. Consequently, the
local minimum seen at around 2 nm will become shallow and the free
energy barrier will be much lower. In addition, as more molecules get
adsorbed on the outer leaﬂet, themembrane undergoes signiﬁcant per-
turbations, which further lowers the free energy barrier, making the
translocation of the cationic group much easier. This is similar to the
conformational change seen for cationic bolaamphiphilic molecules
when they interact with membranes consisting of anionic lipids [35].
In fact, it appears that some AMPs also follow a similar mode of action.
At low concentrations some AMPs such as magainin 2, MSI-78, melittin
and alamethicin lie parallel to the outer leaﬂet, while at high concentra-
tions they were found to penetrate into the membrane and span it,
resulting in the formation of transmembrane pores [36–40]. Moreover,
even bulky cationic dendrimers such as PAMAM have been reported
to locate at the membrane surface at low concentrations, but to pene-
trate into and span the zitterionic bilayer in a transmembrane confor-
mation at high concentrations [41]. Considering the smaller size of the
AM0016/AM0019 molecule and the electrostatic interactions between
the cationic groups of AM0016/AM0019 and the anionic head groups
of the bacterial membrane, it is likely that some AM0016/AM0019
molecules may undergo conformational changes and assume extended
conformations when the drug/lipid ratio is high. It is also possible that
some AM0016/AM0019 molecules will further translocate across the
bacterial membrane, adopting the U-shaped conformation at the inner
leaﬂet. Hence, at high drug concentrations, both the U-shaped and the
extended conformations likely co-exist, perturbing both leaﬂets of the
bacterial membrane. The results suggest that to induce sufﬁcient mem-
brane perturbations, a critical drug/lipid ratio exists, consistentwith the
experimental observation that a minimum inhibitory concentration
(MIC) is required for microbial killing. We next examine the effects of
increasing concentrations of AM0016/AM0019.
2.3. High concentration of AM0016/AM0019 induces signiﬁcant membrane
perturbations
In their transmembrane conformations, both AM0016 and AM0019
interact simultaneously with the three fragments of the bacterial
membrane and this is expected to induce more signiﬁcant membrane
perturbations than would result from the U-shaped conformations.
However, the transmembrane conformation occurs at high drug/lipid
ratios, such as in the case of microbiological killing assays. In contrast,
stoichiometric analysis showed that most biophysical experiments
(e.g., dye-leakage experiment, NMR) were performed at drug/lipid
Fig. 4. (a) Snapshots of AM0016 (a) and AM0019 (b) clusters at high concentrations. Blue
and red dots represent the phosphate groups of POPE and POPG, respectively. Red circles
indicate clusters. (c) Lateral pressures of the bacterial membrane in the presence of
AM0016/AM0019.
Fig. 5. Dye-leakage experiments of AM0016/AM0019. (a) Percent leakage of calcein
from LUV 30 min after addition of AM0016/AM0019 at different drug/lipid ratios using
liposome with DOPE/DOPG = 3/1 mimicking the bacterial inner membrane and DOPC/
cholesterol = 3/1 mimicking the mammalian membrane. (b) Fluorescence intensity
induced by AM0016/AM0019 using living bacterial cells and SYTOX green.
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says [30]. Moreover, the transmembrane conformation likely leads to
membrane instability and disruption. Therefore it is difﬁcult to probe
the transmembrane conformations through biophysical experiments.
Instead, molecular dynamics simulations provide an ideal tool to ex-
plore such features.
In order to understand how the transmembrane conformation af-
fects membrane integrity, we performed microsecond long molecular
dynamics simulations using 4, and 16 molecules of AM0016 and
AM0019 embedded in a membrane patch of 128 lipids, reﬂecting re-
spectively low and high concentrations of AM0016 and AM0019. The
density proﬁles of phosphate atoms in Fig. S2 suggest signiﬁcant mem-
brane perturbations when the AM0016/AM0019 concentration be-
comes high. This leads to signiﬁcant membrane deformation and the
formation of lipid defects ﬁlled with water molecules at high AM0016/
AM0019 concentrations (Fig. S3). As a result, a large number of water
molecules were found to translocate across the membrane, indicating
that the membrane becomes leaky. AM0019 induces little larger mem-
brane deformations than AM0016, which may arise from the bidentate
hydrogen bonds formed between the guanidine groups of AM0019 and
the PO4 groups of lipid molecules. To understand the interactions of the
cationic groupswith the phosphate groups, we calculated the radial dis-
tribution function between the centre of mass of the cationic groups of
AM0016/AM0019 and the centre of mass of the PO4 groups of the
lipid molecules. As expected, AM0019 shows a much higher peak than
AM0016, indicating that the guanidinium group has stronger interac-
tionswith PO4 groups than does the diethalamine group (Fig. S4). In ad-
dition, the apparent area per lipid (AAPL, deﬁned as the area of the
simulation box in the xy plane divided by the number of lipidmolecules
in each leaﬂet) increases with the AM0016/lipid ratio. At the highest
AM0016/lipid ratio (16/128), the AAPL increased almost 40% with re-
spect to that of a pure bacterial membrane (Fig. S5). However, in the
presence of 16 AM0019 molecules, the membrane is signiﬁcantly
distorted (Fig. S3), resulting in only a slight increase in AAPL. Apart
from the perturbations in the membrane structure, both AM0016 and
AM0019 were found to aggregate in the membrane, forming 2-D
clusters in which the central hydrophobic cores stacked together in
the hydrophobic region of the bilayer with the two cationic groups lo-
cated at the head group regions of the two leaﬂets (Fig. 4a and b). This
is associated with a re-distribution of the lipids and the formation of
raft-like domains that are rich in anionic lipids (e.g., POPG) around the
cationic AM0016/AM0019 clusters. These are driven by electrostatics
and signiﬁcantly affect the integrity and the mechanical properties of
the bacterial membrane. In particular, the pressure ﬁeld [42] of the
bacterial membrane was found to change only a little at a low
AM0016/AM0019 concentration, but signiﬁcantly at a high AM0016/
AM0019 concentration (Fig. 4c), with the disappearance of the two
negative peaks. This suggests that the hydrophobic-water interface is
destabilized and is accompanied by a drastic change in the elastic
properties of the bacterial membrane [43].
Our simulation results predict that AM0019 is membrane active and
induces membrane perturbations similar to those of AM0016. To vali-
date the observations from the simulations, we synthesized AM0019
(Fig. S1) and examined membrane leakage using both biophysical and
microbiological experiments. The induced dye-leakage (Fig. 5) and the
MIC value (Table 1) demonstrate that both AM0016 and AM0019 are
membrane active, consistent with our simulation predictions. In the
dye-leakage experiment, AM0019 was found to have slightly larger
inner membrane activity, as revealed by the larger membrane leakage
of AM0019 (Figs. 5a and S6). However, in the microbiological killing as-
says, the antimicrobial activity of AM0019 was shown to be slightly
weaker than that of AM0016 (Table 1). Notice that in the dye-leakage
experiment which uses unilamellar vesicles (LUV), the drug molecules
directly target the membrane, while in the bacterial killing assays, be-
fore targeting the inner membranes, the molecules need to permeate
through the outer membrane ﬁrst, which could be a signiﬁcant and
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periment and the microbe sterilization assays suggests that the outer
membrane servers as a higher diffusion barrier to AM0019 than to
AM0016. These differences may arise as AM0019 shows less hydropho-
bicity due to the presence of the guanidinium group. To verify this, we
conducted a SYTOX green leakage experiment using live bacterial cells
[44]. The results indeed show that AM0016 induced more membrane
perturbations than did AM0019, which conﬁrms that the outer mem-
brane serves as a higher barrier to the inward movement of AM0019
than it does to that of AM0016 (Fig. 5b). The results also suggest that al-
though the rate limiting step of killing of Gram positive bacteria is usu-
ally the disruption of the inner membrane, the permeability of a drug
across the outer membrane (e.g., the thick peptidoglycan layer) can
also affect its antimicrobial activity, at least quantitatively. In a control
experiment using Gram negative strains (Table 1), both AM0016 and
AM0019 showed no activity because of the barrier to permeation pre-
sented by the LPS layer of the Gramnegative strains, which further con-
ﬁrms the role of the outer membrane in antimicrobial activity.
Besides activity, another important issue in the drug develop-
ment is toxicity. In order to examine the toxicity of AM0016 and
AM0019, we performed calcein leakage experiments using a LUV
(DOPC/cholesterol = 3/1) to mimic the mammalian membrane.
Figs. 5a and S7 showed that both AM0016 and AM0019 induce lower
leakage of mammalian membrane than bacterial membrane. To under-
stand membrane selectivity at molecular level, we performed MD sim-
ulations using different number of AM0016 with model mammalian
and bacterial membranes, corresponding to different drug/lipid ratios.
Fig. S8 shows that AM0016 adsorbs on the bacterial membrane much
faster than on themammalianmembrane, as a result of favourable elec-
trostatic interactions. Moreover, AM0016 was found to penetrate more
into the bacterial membrane than into the mammalian membrane, as
revealed by the distance between AM0016 and the bilayer centre. We
then varied the number of drug/lipid ratio in the MD simulations and
used the electrostatic potential to characterize the surface concentra-
tion of AM0016 on both membranes [45]. As shown in Fig. S9, the bac-
terial membrane displays a very negative electrostatic surface potential
comparedwith themammalianmembrane, whose electrostatic surface
potential is neutral. Asmore number of AM0016 adsorbed on themem-
brane surface, the electrostatic surface potential shifts to more positive
values. Fig. S9 clearly showed that even after the adsorption of 9
AM0016 molecules, the bacterial membrane still displays patches
with negative potential, while the surface potential of mammalian
membrane is saturated after adsorption of 4 AM0016 molecules. This
suggestedmuch higher surface concentrations of AM0016 on the bacte-
rial membrane than on the mammalian membrane, which may be re-
sponsible for its selectivity towards the bacterial membrane.
We also performed hemolysis test for both AM0016 and AM0019
using red blood cells (HC50) and cytotoxicity test using lactate dehydro-
genase (LDH) release assays using human corneal ﬁbroblast cells. The
results showed that both AM0016 and AM0019 displayed much higher
HC50 values than their respectiveMIC values, suggesting that selectivity
of the two compounds were towards the bacterial membrane. Further-
more, toxic levels of AM0016 and AM0019 based on LDH release assays
also revealed a higher lethal dosage of AM0016 and AM0019 than the
MIC values, consistent with the simulation results, the calcein leakage
and the hemolysis data. On the other hand, compared to AM0016,
AM0019 is less toxic and exhibits higher hemolysis values (HC50) andTable 2
Lethal dosages of xanthone analogues (μg/mL).
Description XAN-016 AM0016 AM0019
aHC50 Rabbit blood cell N200 19.6 62.6
bLDH Human corneal ﬁbroblast cells ND 5.71 21
a Concentration required to kill 50% red blood cells.
b Lactate dehydrogenase assay using human corneal ﬁbroblast cells.lethal dosages (Table 2), as a result of the reduced hydrophobicity of
the guanidinium group of AM0019 with respect to the diethylamide
group of AM0016. The above results suggest that the pharmacophore
model proposed here is a useful molecular template for the practical
design of membrane active molecules.
3. Discussion
From the above MD results, a three-step action mechanism of the
bolaamphiphiles AM0016 and AM0019 can be deduced: adsorption–
translocation–disruption. Upon adsorption on to the bacterial inner
membrane, the molecule ﬁrst takes a “U-shaped conformation” with
both cationic groups interacting with the charged outer leaﬂet,
perturbing only one extracellular hydrophobic–hydrophilic interface.
At low concentrations, the molecules remain there because the free en-
ergy barrier is too high for the cationic group to further penetrate into
the hydrophobic region of the bacterial membrane. As increasing num-
bers of molecules get adsorbed onto the membrane, the outer leaﬂet of
the inner membrane is gradually neutralized, the drug molecules begin
to experience the electrostatic attraction from the inner leaﬂet and the
membrane starts to deform, resulting in a reduction in the free energy
barrier for translocation of the molecules. This is followed by a confor-
mational change from the U-shaped conformation to a transmembrane
conformationwhere one of the cationic groups crosses the hydrophobic
region to interactwith the other charged surface, perturbing bothmem-
brane interfaces. It is also possible that somemolecules fully translocate
across the lipid tail region and adopt U-shaped conformations at the
inner leaﬂet, particularly at high concentrations. When a sufﬁcient
number of molecules are in the transmembrane conformation, the
membrane undergoes signiﬁcant deformations and large lipid defects
form, leading to the translocation of large numbers of water molecules.
Meanwhile, 2-D aggregates begin to form across the membrane and
cause a redistribution of the anionic lipids around clusters of the mole-
cules, resulting in changes in the elastic properties of themembrane, en-
suing in membrane destabilization.
In the proposed pharmacophore model, a minimum of three frag-
ments are needed: a central hydrophobic core and two cationic terminal
groups; each fragment has a particular role. The hydrophobic scaffold
plays an important role in partitioning into the bacterial membrane.
The MD simulations identify some unique properties that endow
alpha-mangostin as an excellent hydrophobic scaffold. Firstly, alpha-
mangostin demonstrates enough hydrophobicity to partition into the
lipid tail region of the bacterial membrane. Second, even in the trans-
membrane conformation, AM0016/AM0019 does not achieve a perfect
hydrophobic–hydrophilic match with the bacterial membrane due to
the presence of the polar groups in the alpha-mangostin scaffold. This
results in “disruptive amphiphilicity”, which is believed to induce lipid
defects [30]. Thirdly, the aromaticity and planarity of the ring structure
of the alpha-mangostin molecules enable this scaffold to stack in the
lipid tail region of the bacterial membrane, as shown by the 2-D aggre-
gates of AM0016 and AM0019. The 2-D aggregates, together with the
cationic groups, further induce membrane deformation and lipid re-
organization, forming micro-domains that consist of positively charged
AM0016/AM0019 aggregates surrounded by anionic lipids (e.g., POPG).
Besides the hydrophobic fragment, the two cationic fragments of
AM0016 and AM0019 preferentially interact with the anionic head
groups of the bacterial membrane, leading to selectivity towards bacte-
rial membranes. The results of AM0016 and AM0019 suggest that to
achieve strong interactions with the anionic head groups, high pKa
values, low hydrophobicity and the ability to form multiple hydrogen
bondswith the phosphate groups are the important biophysical proper-
ties of the cationic fragments. Additionally, other properties of the
cationic groups such as the number of positive charges, the shape and
size of the cationic groups will likely also modulate the interactions
with the anionic head groups of the membrane. There is also the possi-
bility of manipulating the linkers that join the hydrophobic and cationic
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study because the current study is really to demonstrate proof-of-
principle; we have minimized the incumbent complexities. However, it
is very likely that the lengths and chemical nature of the linkers and
the associated ﬂexibility will also inﬂuence the barriers that limit the
translocation process. In summary, these biophysical parameters provide
the basis for further design of new membrane active peptidomimetics.
Considering the fact that the head groups of bacterial membranes are
negativewhile themammalianmembrane is neutral, the pharmacophore
model can also achieve selectivity by choosing appropriate cationic frag-
ments that can favourably interact with the anionic head groups of the
bacterial membrane via electrostatic interactions. As exempliﬁed in the
MD simulations (Figs. S8 and S9), AM0016 binds to the bacterial mem-
brane with faster kinetics and higher afﬁnities than to the mammalian
membrane. As a result, AM0016 can accumulate up to amuch higher sur-
face concentration on the bacterial membrane than on the mammalian
membrane, achieving the selectivity, which is consistentwith the interfa-
cial model [30]. The selective interaction of the pharmacophoremodel to
the bacterial membrane was supported by the results of calcein leakage,
hemolysis and LDH release assays (Table 2). Moreover, we have shown
that topical application of AM0016 has no obvious toxicity to the eyes
of mouse and rabbit and does not interfere with wound healing [25]. Al-
together, these data demonstrate that the potential of the
pharmacophoremodelwith bolaamphiphilic structure can be further op-
timized into new peptidomimetics with potential clinical applications, at
least for topical applications.
Finally, although the action mechanism of the pharmacophore
model is exempliﬁed using mangostin analogues AM0016 and
AM0019, the choice of the hydrophobic scaffold is not limited to
alpha-mangostin. In principle, any hydrophobic molecule with afﬁnity
for the lipid tails can be a possible candidate as the hydrophobic scaf-
fold. Indeed, different groups have used different hydrophobic scaffolds
to design bolaamphiphilic antimicrobials. Fig. S10 shows the structure
of some other membrane active antimicrobials: XF-73 (in phase I clini-
cal trials) [20], brilacidin (in phase II clinical trials) [46,47] and LTX-109
(in phase II clinical trials) [21], mPE [48] and BPMTAs [23], all have a
bola-like structure with a central hydrophobic core and two cationic
arms, suggesting a mode of action similar to that of AM0016/AM0019,
particularly at high concentrations. In addition, the pharmacophore
model can be further extended by optimizing each fragment or even
by adding additional cationic groups. For example, CSA-13 [49] appears
to be a variation of our model in which the central hydrophobic core is
replaced by sterol decorated with more than two cationic groups.
Finally, toxicity and activity correlate with each other; thus in order to
achieve high selectivity one needs to balance these two factors. For ex-
ample, mammalianmembranes often consist of zitterionic lipids with a
large content of cholesterol. This suggests that design strategies could
beneﬁt from minimizing the afﬁnity of the scaffold with cholesterol
moieties.
4. Conclusion
In summary, we demonstrated a simple and yet generalizable
pharmacophore model with its detailed mode of action for the ab initio
design of membrane activemolecules against Gram positive pathogens.
The bola-like structure of the pharmacophore model consists of one
hydrophobic scaffold and two cationic terminal groups, whichwere de-
signed to complementarily interact with the lipid tails and the head
groups of the bacterial membrane, respectively. CombiningMD simula-
tions, biophysical and microbiological experiments to investigate two
derivatives of the pharmacophore model, we ﬁnd compelling evidence
supporting the proposed mode of action. Although the safety of the
two model compounds needs additional examinations, the approach
employed and the pharmacophore model proposed in this study
demonstrated the potential for further development of compounds
with improved selectivity. Further improvements are currently beingcarried out to optimize each fragment of the pharmacophore model in
order to design better antimicrobials with lower toxicity [50].
5. Methods
5.1. Molecular dynamics simulations
Themain lipids of bacterialmembrane are POPE and POPG. To have a
general model for the bacterial membrane, we employ a mixture of
POPE and POPG at a ratio of 3/1 to represent the bacterial membrane,
which has been used extensively in other simulation and experimental
studies [51–54]. Themembrane patchwith 72 lipidmolecules was used
in umbrella sampling molecular dynamics (MD) simulations. The
Gromos53a6 force ﬁeld [55] was used in all the MD simulations. ATB
[56] was used to construct the topology of the drug molecules. The
translocation free energies of a molecule across the bacterial membrane
were calculated from umbrella sampling and weighted histogram anal-
ysis method (WHAM) [34,57] using the GROMACS 4.5 package [58].
Due to the introduction of biased potential along the chosen reaction
coordinate, umbrella sampling simulations can signiﬁcantly enhance
the phase space sampling. The post-processing algorithm WHAM,
which is based on analysis of the data from all the intermediate states
at once, reduces the number of cycles and grantees efﬁciency, demon-
strating advantages over other methods such as multiple histogram
reweighting method by Ferrenberg and Swendsen [59]. In the simula-
tions, each umbrella window runs for at least 200 ns (Table S1). To un-
derstand themembrane afﬁnities of different hydrophobic scaffolds, we
also performed a series of conventional molecular dynamics (Table S2).
The surface potential of the model membranes was calculated used the
APBS plugin of PYMOL [60,61]. In order to study the aggregation of
AM0016/AM0019 on the mechanical properties of the membrane, we
calculated the pressure ﬁeld of the bacterial membrane using a custom-
ized version of GROMACS [62]. The details of the parameters used in the
simulations can be found in the supplementary materials.
5.2. Experimental methods
5.2.1. Susceptibility testing
Susceptibility testing of XAN-016, AM0016 and AM0019 was
performed using the broth macro-dilution method in Mueller Hinton
Broth (MHB) following Clinical and Laboratory Standards Institute
(CLSI) guidelines. Both compounds were ﬁrst dissolved in N,N-
dimethylformamide (DMF) and the stock solutions of 1000 μg/mL
were prepared. Serial two-fold dilutions of the compounds were then
prepared in MHB, Cation Adjusted in test tubes. The concentration of
the above-mentioned inoculum suspension was adjusted in MHB until
each tube contained approximately 5 × 105 Colony Forming Units
(CFU)/mL and incubated at 35 °C for 20 to 22 h. The bacteria used in
this study were MRSA DM21455, MRSA 9808R, BC 11778 and Clinical
isolates S. aureus DM4001. The inoculum suspension was made from
isolated colonies selected from an 18- to 20-hour Tryptic Soy Agar
(TSA) plate using the direct colony suspension method as prescribed
by the CLSI standard.
5.2.2. Hemolysis
Hemolysiswas determined as described previously [24,50]. All proce-
dures for isolating blood fromNewZealandwhite rabbitswere approved
by IACUC Singhealth and performed according to the standards of the
Association for the Research in Vision and Ophthalmology.
5.2.3. In vitro cytotoxicity study using lactate dehydrogenase assay
The cytotoxicity of individual compounds screened was determined
by the lactate dehydrogenase (LDH) assay. In brief, human corneal
ﬁbroblast cells were plated at a density of 10,000 cells per well in a
96-well opaque white plate (SPL Life Sciences Inc). Test compounds of
various concentrations and controls were added to appropriate wells
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the test compounds, the plates were removed from 37 °C incubator and
equilibrated to 22 °C for 30 min. One hundred microliters of Cyto-TOX
One reagent (Promega Inc. USA) was added to each well and the LDH
assay was performed according to the manufacturer's instructions.
Fluorescence was assessed at an excitation wavelength of 560 nm and
an emission wavelength of 590 nm using a micro-plate reader (Tecan
Inﬁnite 200 Pro). The cells exposed to 1% Triton X-100 were used as a
positive control and treated as maximum releasing of LDH. The percent
speciﬁc cytotoxicity of each compound was determined using the
formula below:
% Cytotoxicity ¼ Iexperiments
 
− Inegative controls
 h i
= Ipositive controls
 
− Inegative controls
 h i
 100
where I = intensity measured.
5.2.4. SYTOX green membrane permeabilization assay
The protocol wasmodiﬁed based on themethod of Rathinakumar et
al. [44] and has been reported [25]. Brieﬂy, overnight a culture of clinical
isolate S. aureus DM4001 (source: eyes) was harvested at exponential
phase. Bacteria were then washed at least 3 times and suspended in
20mMPBS until OD620 (optical density at 620 nm) of 0.09was obtain-
ed. The bacterial suspension was then incubated with 3 μM SYTOX
Green (Invitrogen) in dark conditions for 5 min. Then, the mixture
was transferred to a stirring cuvette and the ﬂuorescence emission
was monitored using an excitation wavelength of 504 nm and an
emission wavelength of 523 nm until the signal was stabilized. Desired
concentration of AM0016 and AM0019was then added and the ﬂuores-
cence change was measured and recorded. Both compounds were
dissolved in DMF and the ﬁnal % of DMF in the culture was b0.1%. 0.1%
DMF had negligible effect on the SYTOX Green ﬂuorescence intensity.
Experiments were repeated at least two times and were reproducible.
Data from one experiment is presented.
5.2.5. Calcein-loaded LUV leakage study
The release of calcein from the large unilamellar vesicles (LUVs)was
studied as previously reported [24]. In brief, the lipids (DOPE/DOPG =
75/25 to mimic bacterial membrane and DOPC/cholesterol = 75/25 to
mimicmammalianmembrane)were dissolved inmethanol/chloroform
(1:2, by volume) andwere dried gently using a constant streamof nitro-
gen gas until a thin lipid ﬁlmwas formed. The ﬁlmwas completely dried
byplacing theﬁlmunder vacuum for at least 2 h. 80mMcalcein solution
was prepared by suspending calcein powder (Sigma Aldrich) in HEPES
buffer (50 mM HEPES, 100 mM NaCl, 0.3 mM EDTA, pH 7.4). NaOH so-
lution was added until all calcein suspension was dissolved. Then, the
pH of the calcein solution was adjusted to pH 7.4 by adding HCl slowly.
Then, the dried lipid ﬁlm was hydrated using the calcein solution pre-
pared) to obtain a ﬁnal lipid concentration of 30 mM. The hydrated
lipids were freeze-thawed in liquid nitrogen and warm water for 7 cy-
cles. 100nmhomogenous LUVswere then prepared by using an extrud-
er with a polycarbonate membrane (Whatman, pore size 100 nm). The
extrusion was done for at least 10 cycles. Sephadex G-50 was used to
purify the calcein-loaded LUVs from the free calcein. The concentration
of calcein loaded LUVswas determined using total phosphorus determi-
nation assay. An aliquot of the LUV suspension was added into a stirred
cuvette at various concentrations of AM0016 and AM0019 solution in
DMF to obtain the desired compounds to lipid ratios of 1/2, 1/4, 1/16,
1/64, and 1/256. The ﬁnal concentration of lipid was 50 μM and the
ﬁnal percentage of DMF is b0.2%. Complete leakage was assumed by
adding 2% Triton X-100. Control experiment using 0.2% of DMF showed
that leakage of calcein from the LUVs was negligible. The calcein re-
leased was monitored using a Photon Technology International Model
814 ﬂuorescence spectrophotometer at an excitation wavelength of490 nm and an emission wavelength of 520 nm. Percentage of leakage
(%L) was calculated with %L = [(It− I0) / (I∞ − I0)] × 100], where I0
and It are intensity before and after addition of AM0016 or AM0019 re-
spectively and I∞ is the intensity after the addition of 2% triton X-100.
5.2.6. Chemical synthesis
The details of the chemical synthesis can be found in supplementary
materials.
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